OncoMatch/Clinical Trials/NCT06656598
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Is NCT06656598 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Carboplatin and Paclitaxel for stage iii nsclc.
Treatment: Carboplatin · Paclitaxel · Cemiplimab · Cemiplimab (maintenance) — The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR activating mutation
Patients with an activating EGFR mutation ... [excluded]
Required: ALK fusion
ALK ... translocation [excluded]
Required: ROS1 fusion
ROS1 translocation [excluded]
Disease stage
Required: Stage IIIA, IIIB, IIIC
Excluded: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1 therapy
Previously received a treatment with anti-PD1/PDL1, anti-CTLA, or other antineoplastic immunotherapy or chemotherapy for NSCLC
Cannot have received: anti-PD-L1 therapy
Previously received a treatment with anti-PD1/PDL1, anti-CTLA, or other antineoplastic immunotherapy or chemotherapy for NSCLC
Cannot have received: anti-CTLA-4 therapy
Previously received a treatment with anti-PD1/PDL1, anti-CTLA, or other antineoplastic immunotherapy or chemotherapy for NSCLC
Cannot have received: cytotoxic chemotherapy
Previously received a treatment with anti-PD1/PDL1, anti-CTLA, or other antineoplastic immunotherapy or chemotherapy for NSCLC
Cannot have received: radiotherapy
History of thoracic radiotherapy
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1.5.109/l, platelets ≥ 100.109/l, hemoglobin ≥ 9 g/dl
Kidney function
estimated creatinine clearance ≥ 45 ml/min
Liver function
bilirubin ≤1.5xuln, ast alt ≤3xuln, albumin ≥28g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify